Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

LGD-4033 and MK-2866 Interaction: Avoid | Peptide Database

Compound Profiles LGD-4033 Selective Androgen Receptor Modulator | Lean Mass LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its t

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take LGD-4033 with MK-2866?

Combining LGD-4033 with MK-2866 is not recommended. Both LGD-4033 and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and MK-2866 safe together?

This combination carries significant risk. Both LGD-4033 and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and MK-2866?

Both LGD-4033 and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and MK-2866?

LGD-4033 has a half-life of ~24-36 hours and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Turinabol increases muscular strength and power output without the water retention and significant body mass increases associated with aromatizing compounds. This makes it particularly suited for athletes competing in weight-class sports or those requiring a high strength-to-weight ratio. Through enhanced red blood cell production and improved creatine phosphate resynthesis, turinabol supports aerobic and anaerobic endurance. Athletes report improved recovery between training sessions and sustained performance during competition periods. The East German doping program selected turinabol specifically for speed and power athletes, including sprinters, swimmers, and throwers. The compound enhances neuromuscular efficiency and explosive power without the weight penalty of water retention. Turinabol promotes gradual, quality lean tissue gains during caloric surplus periods. While the rate of gain is slower than with aromatizing orals like Dianabol, the gains are predominantly lean tissue with minimal fat or water, and are generally more maintainable post-cycle. During cutting phases, turinabol supports nitrogen retention and anti-catabolic effects, helping preserve lean muscle tissue while in a caloric deficit. The absence of water retention means all visible changes reflect actual tissue composition.

Source: peptide-db.com ↗

Research Indications

First-line pharmacotherapy for lifelong and acquired premature ejaculation. Clinically proven to increase intravaginal ejaculatory latency time (IELT), improve perceived control over ejaculation, and reduce personal distress related to PE. Improved ejaculatory control leads to greater sexual satisfaction for both the individual and their partner, as measured by validated patient-reported outcome instruments in clinical trials.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Topical minoxidil is the FDA-approved formulation for hair loss, available as a 2% or 5% solution or foam. The 5% formulation is more effective than 2% for men, while 2% is the standard approved concentration for women. Applied directly to dry scalp in affected areas, it should be left on for at least 4 hours before washing. The foam formulation dries faster and causes less scalp irritation than the solution, which contains propylene glycol. Consistency is critical, as discontinuation leads to loss of any gained hair within 3-6 months. Male pattern hair loss (standard) 1mL of 5% solution or half a capful of 5% foam Twice daily (morning and evening) Topical application to affected scalp areas Female pattern hair loss 1mL of 2% solution or 5% foam once daily Once to twice daily depending on formulation Maintenance protocol 1mL of 5% solution or foam Once daily (some users step down from twice daily after stabilization)

Source: peptide-db.com ↗
Side effects

Common Side Effects

Injection site reactions Mild fatigue during adaptation Potential hypoglycemia

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides